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Introduction
Endometrial carcinoma is a common gynaecological 
malignancy in developed countries. It affects postmeno-
pausal women predominantly, but 25% of cases occur in 
premenopausal women, 5% of whom are younger than 
40 years of age.1  Complex atypical hyperplasia (CAH) of the 
endometrium is a precursor to endometrial carcinoma, with 
a progression rate to carcinoma of 10%. Women with stage 
I, grade 1 endometrial carcinoma treated by hysterectomy, 
have a 99.2% five-year survival. The high cure rate of the 
disease shifts the treatment focus to issues of quality of 
life subsequent to successful treatment.2 Young nulliparous 
women with CAH raise the possibility of fertility-sparing 
treatment. The treatment approach to CAH is viewed in the 
same light as that pertaining to early-stage endometrial 
carcinoma. In both scenarios, fertility-sparing treatment (with 
subsequent successful pregnancies) has been described. The 
conservative management of CAH poses several challenges 
with regard to adequate sampling of the endometrium, as 
well as optimal treatment and follow-up monitoring.3 The 
current case illustrates successful conservative management 
of CAH.  
Case study
A 31-year-old nulligravida presented with primary infertil-
ity and a long-standing history of oligomenorrhoea. Her 
menarche occurred at 11 years of age and her medical and 
surgical history were noncontributory. A clinical examination 
revealed a weight of 79.1 kg, with a body mass index (BMI) 
of 25.8. Systemic and gynaecological examinations were 
within normal limits. Hormone analysis (including thyroid 
function and prolactin) was normal. A laparoscopy, hyster-
oscopy and endometrial sampling were performed to assess 
fertility status. The laparoscopy documented a normal uterus 
and pelvis. Endometrial histology diagnosed CAH (Figure 1.) 
The patient received medroxyprogesterone acetate (MPA) 
10 mg daily for a month, and a repeat hysteroscopy was 
performed. At this stage, the endometrium appeared to be 
atrophic, and sampling was difficult, requiring a resectoscope 
to obtain endometrial tissue. CAH was present on histology. 
A levonorgestrel-releasing intrauterine system was inserted 
and removed three months later. At this stage, the hysteros-
copy was normal and histology showed decidual changes 
in the stroma and a thin atrophic endometrium (Figure 2). 
Clomiphene citrate ovulation induction was started.
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Figure 1: Complex endometrial glandular appearance with back-to-
back arrangement and areas with nuclear atypia and occasional mitotic 
figures
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Discussion
Bokhman divided endometrial carcinoma into two broad 
categories: stage I and II.4 Type I tumours comprise low-
grade endometrioid carcinomas with good prognosis, and 
type II tumours represent high-grade carcinomas with poor 
prognosis.4 Bokhman’s division is based on the clinical, 
metabolic and endocrine features of the patient. Obesity and 
chronic anovulation predispose to unopposed oestrogen 
endometrial stimulation, with proliferation and subsequent 
hyperplasia.2  Thus, Bokhman type I tumours are associated 
with obesity and anovulation. In these cases, hyperplasia 
commonly coexists with grade 1 endometrial carcinoma. 
Bokhman type II tumours arise de novo, and are less likely 
to be associated with concomitant hyperplasia. The current 
case was atypical as the patient had a normal BMI. However, 
the history of oligomenorrhoea suggests long-standing 
anovulation.
CAH of the endometrium is a precursor to endometrial 
carcinoma. Metachronus endometrial carcinoma occurs in 
48% of cases.5 The classification of endometrial hyperplasia 
is based on the World Health Organization scheme (WHO94). 
This system, based on a study by Kurman, correlates 
cytological atypia and glandular complexity with increased 
risk of carcinoma6 (Table I).
Fertility-sparing management of CAH requires sensitive and 
specific pretreatment detection of coexisting endometrial 
carcinoma. Dilatation and curettage, and Pipelle® endometrial 
biopsy, both have sampling limitations. Approximately 60% 
of dilatation and curettage specimens sample less than 50% 
of the uterine cavity.5 The flexible Pipelle® device may be 
deflected by mass lesions, e.g. polyps and myomas, which 
prevent adequate endometrial sampling. A comparative 
study on CAH diagnosed by dilatation and curettage and 
Pipelle® biopsy documented missed carcinoma in 27% and 
46%, respectively, in hysterectomy specimens, subsequent 
to the sampling.7  
Hysteroscopy does not significantly increase carcinoma 
detection. Precancerous lesions cannot be visualised with 
hysteroscopy. Hysteroscopic appearances cannot distinguish 
between CAH and carcinoma. Transvaginal ultrasonography 
measurement of an endometrial thickness of 5 mm or more 
has been shown to detect 95% of endometrial carcinomas in 
postmenopausal women.8 The overlap of normal endometrial 
thickness with carcinoma limits the value of ultrasound 
in premenopausal women. Histochemical markers, e.g. 
oestrogen and progesterone receptors or phosphatase and 
tensin homolog gene expression, may serve as predictors to 
treatment response, but prospective data are lacking.1,9  
Fertility-sparing management of CAH aims to completely 
reverse the pathology to normal endometrial function and 
prevent progression to endometrial cancer. Progesterone 
counterbalances the mitogenic effects of oestrogen and 
induces secretory differentiation of the endometrium. 
Currently, the dose, type, schedule and optimal route of 
progesterone administration remains to be determined. The 
available formulations are represented in Table II. 
Figure 2: Thin endometrial lining, with desidual changes in the stroma
Table I: Progression rates of precursor lesions of the endometrium6
Pathology Number of patients
(n = 170)
Number that 
regressed (%)
Number that 
persisted (%)
Number that progressed 
to carcinoma (%)
Simple hyperplasia 93 74 (80) 18 (19) 1 (1)
Complex hyperplasia 29 24 (80) 5 (17) 1 (3)
Simple atypical hyperplasia 13 9 (69) 3 (23) 1 (8)
Complex atypical hyperplasia 35 20 (57) 5 (14) 10 (29)
Table II: Hormonal treatment of atypical endometrial hyperplasia
Treatment Dosage or length
Medroxyprogesterone acetate 10-20 mg daily, or cyclic 12-14 
days per month
Depot medroxyprogesterone 150 mg intramuscularly, every 
three months
Micronised vaginal progesterone 100-200 mg daily, or cyclic  
12-14 days per month
Megestrol acetate 40-200 mg daily
Levonorgestrel-containing 
intrauterine device
1-5 years
Case Study: Fertility-sparing treatment in a young patient with complex atypical hyperplasia of the endometrium
32 2014 Vol 6 No 1South Afr J Gynaecol Oncol
Regression of hyperplasia has been observed in 80-90% 
of individuals receiving MPA at a dose of 10 mg daily for 
12-14 days per month. Systemic progestin side-effects 
include water retention and mastalgia. The levonorgestrel-
releasing intrauterine system and micronised vaginal 
progesterone provide alternatives to oral therapy. The 
vaginal route negates the systemic side-effects and 
enhances compliance. Several studies have documented 
the efficacy of the levonorgestrel-releasing intrauterine 
system. These studies include cases with well differentiated 
endometrial carcinomas. Post-treatment sampling of the 
endometrium reveals CAH regression in up to 100% of cases, 
and carcinoma regression in up to 70%.10 Because of atrophy 
that is induced by progestin, sampling may be difficult. In the 
current case, a resectoscope was used to obtain tissue after 
initial therapy. Hormonal resistance may occur in 30% of 
cases. On regression of CAH, the underlying hormonal cause, 
e.g. anovulation, should be appropriately addressed. In the 
current case, ovulation induction with clomiphene citrate 
was used. Meticulous follow-up is warranted as recurrence 
of hyperplasia occurs in 30% of cases.11 These relapses can 
be successfully re-treated, but require adequate follow-
up and resampling.1 An alternative to progestin therapy is 
gonadotropin-releasing hormone agonist treatment, which 
has a success rate of 85%. Systemic side-effects, e.g. hot 
flushes, limit its use.
Conclusion
The current case of CAH illustrates the management principles 
of conservative treatment to retain fertility. The pivotal role 
of adequate pretreatment sampling and post-treatment 
evaluation of the endometrium is underscored by the use 
of a resectoscope to obtain tissue after initial treatment. The 
case further documents the fact that progestin treatment 
is the treatment of choice. The levonorgestrel-releasing 
intrauterine system offers adequate progestin exposure of 
the endometrium, without systemic side-effects. Fertility-
sparing CAH treatment requires meticulous pretreatment 
evaluation to exclude invasive carcinoma, as well as post-
treatment surveillance to detect recurrence.
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